FUDOSTEINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C6H13NO3S
Molecular Weight	179.237
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@@H](CSCCCO)C(O)=O

InChI

InChIKey=KINWYTAUPKOPCQ-YFKPBYRVSA-N

InChI=1S/C6H13NO3S/c7-5(6(9)10)4-11-3-1-2-8/h5,8H,1-4,7H2,(H,9,10)/t5-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C6H13NO3S
Molecular Weight	179.237
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549

Fudosteine is a derivative of cysteine developed and approved in Japan for the treatment of such diseases as bronchial asthma, chronic bronchitis, pulmonary emphysema, bronchiectasis, pulmonary tuberculosis, pneumoconiosis, atypical mycobacterial disease and diffuse panbronchiolitis. Fudosteine acts as a mucoactive agent, enabling mucin secretion. Although exact mechanism of action is unknown, it is supposed that fudosteine inhibits MUC5AC expression.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mucin-5AC 2 Target ID: P98088\|\|\|Q8N4M9 Gene ID: 4586.0 Gene Symbol: MUC5AC Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Bronchial asthma 50 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22349417	Palliative	Approved 8583	Unknown Approved Use Unknown
Chronic bronchitis 52 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22349417	Primary	Approved 8583	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 175 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22349417	Primary	Approved 8583	Unknown Approved Use Unknown
Bronchiectasis 3 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22349417	Primary	Approved 8583	Unknown Approved Use Unknown
Pulmonary tuberculosis 17 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549	Primary	Approved 8583	Unknown Approved Use Unknown
Pneumoconiosis 1 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549	Primary	Approved 8583	Unknown Approved Use Unknown
Atypical mycobacterial disease 1 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549	Primary	Approved 8583	Unknown Approved Use Unknown
Diffuse panbronchiolitis 1 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549	Primary	Approved 8583	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
10.13 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16898073/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		FUDOSTEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.75 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16898073/	400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:		FUDOSTEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
23.95 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16898073/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		FUDOSTEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
24.91 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16898073/	400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:		FUDOSTEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16898073/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		FUDOSTEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16898073/	400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:		FUDOSTEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
600 mg single, oral Highest studied dose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/16408815/	healthy Health Status: healthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16408815/	Sources: https://pubmed.ncbi.nlm.nih.gov/16408815/
400 mg 3 times / day multiple, oral Studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16898073/	healthy Health Status: healthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16898073/	Sources: https://pubmed.ncbi.nlm.nih.gov/16898073/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP19A1 429 CYP1A2 2153	CYP 303 P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/743139#sid=144205738	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671199#sid=170465764	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671197#sid=170465764	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=170465764	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=170465764	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346984#sid=144205738	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=170465764	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=144205738	no
CYP 303	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16898073/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/588834#sid=144205738

PubMed

Title	Date	PubMed
Effect of fudosteine on mucin production.	2008-11	18579549
Inhibition of endotoxin- and antigen-induced airway inflammation by fudosteine, a mucoactive agent.	2005	15649854
Effects of SS320A, a new cysteine derivative, on the change in the number of goblet cells induced by isoproterenol in rat tracheal epithelium.	1998-05	9639062

Patents

Sample Use Guides

In Vivo Use Guide

Fudosteine is an expectorant given orally in a dose of 400mg three times daily.

Route of Administration: Oral

In Vitro Use Guide

The human pulmonary mucoepidermoid carcinoma cell line NCI-H292 was cultured in RPMI 1640 media that contained 10% foetal bovine serum, penicillin (100 U*mL-1), streptomycin (100 mg*mL-1) and HEPES (25 mM) at 37C in a humidified 5% CO2 water-jacketed incubator. Fudosteine suppresses TNF-alpha-induced MUC5AC mucin secretion,albeit only at the concentration of 1 mM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:27:51 GMT 2025` Edited by `admin` on `Mon Mar 31 18:27:51 GMT 2025`
Record UNII	UR9VPI71PT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FUDOSTEINE

Official Name

English

CLEANAL

Preferred Name

English

Fudosteine [WHO-DD]

Common Name

English

FUDOSTEINE [JAN]

Common Name

English

FUDOSTEINE [MART.]

Common Name

English

fudosteine [INN]

Common Name

English

(-)-3-((3-HYDROXYPROPYL)THIO)-L-ALANINE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C74536